PARP inhibitors

DRUG2 trials

Sponsors

University Hospital, Caen, Xiaoxiang Chen

Conditions

CancerClinical MarkerOvarian CancerPARP Inhibitor

Unknown Phase

Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)

CompletedNCT04326023

University Hospital, CaenCancer

Start: 2020-02-09End: 2020-05-03Updated: 2021-03-11

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

Xiaoxiang ChenClinical Marker, Ovarian Cancer, PARP Inhibitor

Start: 2020-12-15End: 2023-11-30Target: 60Updated: 2021-01-20

Related Papers

Therapie-assoziierte myeloische Neoplasien: Woran bei Blutbildveränderungen unter Therapie mit PARP-Inhibitoren gedacht werden sollte

Kompass Onkologie2022-01-01

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.

2020-12-18174 citations